| Contributors |
|
xiii | |
| Preface |
|
xix | |
| Acknowledgments |
|
xxi | |
|
1 Delivery strategies for immune checkpoint blockade |
|
|
1 | (30) |
|
|
|
|
|
|
|
|
|
|
|
1 | (2) |
|
2 Systemic delivery of ICIs |
|
|
3 | (15) |
|
|
|
18 | (5) |
|
|
|
23 | (8) |
|
|
|
24 | (7) |
|
2 Delivery strategies for ex vivo and in vivo T-cell reprogramming |
|
|
31 | (32) |
|
|
|
|
|
|
|
|
|
|
|
|
|
31 | (2) |
|
2 Engineering techniques for drug delivery to T-cells |
|
|
33 | (9) |
|
3 Therapeutic applications of delivery strategies for T-cell reprogramming in cancer |
|
|
42 | (13) |
|
4 Conclusions and future directions |
|
|
55 | (8) |
|
|
|
55 | (1) |
|
|
|
55 | (8) |
|
3 Targeting natural killer cells in cancer immunotherapy |
|
|
63 | (20) |
|
|
|
|
|
63 | (1) |
|
2 Exploiting NK cell immunobiology for localized therapy |
|
|
64 | (1) |
|
3 Manufacturing of NK cell therapies |
|
|
65 | (2) |
|
4 Challenges to NK cell therapy and the delivery of NK cells to target tumors |
|
|
67 | (4) |
|
5 Immunometabolic reprogramming of NK cells in cancer |
|
|
71 | (2) |
|
6 Soluble factors modulating NK cell therapy |
|
|
73 | (2) |
|
7 Enhancing the immunotherapeutic potential of NK cells: Improving delivery, specificity, and activity |
|
|
75 | (1) |
|
|
|
76 | (7) |
|
|
|
76 | (7) |
|
4 Delivery strategies for reprogramming tumor-associated macrophages |
|
|
83 | (34) |
|
|
|
|
|
|
|
83 | (4) |
|
2 Delivery strategies for small molecule inhibitors in macrophage reprogramming |
|
|
87 | (4) |
|
3 Nucleic acid delivery systems |
|
|
91 | (7) |
|
4 Cytokine delivery for TAM repolarization |
|
|
98 | (3) |
|
5 Antibody-mediated therapy |
|
|
101 | (3) |
|
6 Biomaterial based macrophage modulation |
|
|
104 | (1) |
|
|
|
105 | (3) |
|
|
|
108 | (9) |
|
|
|
109 | (1) |
|
|
|
109 | (8) |
|
5 Delivery strategies of RNA therapeutics for ex vivo and in vivo B-cell malignancies |
|
|
117 | (30) |
|
|
|
|
|
|
|
|
|
117 | (3) |
|
2 RNAi-conjugates for ex vivo and in vivo delivery of RNAi therapeutics to malignant B-cells |
|
|
120 | (7) |
|
3 Nanocarrier-based delivery of RNAi therapeutics for the in vivo manipulation of malignant B-cells |
|
|
127 | (13) |
|
|
|
140 | (7) |
|
|
|
141 | (6) |
|
6 Targeting tumor-associated neutrophils in immunotherapy |
|
|
147 | (16) |
|
|
|
|
|
1 Reducing the number of tumor-associated neutrophils |
|
|
147 | (5) |
|
2 Blocking immunosuppressive activity of tumor-associated neutrophils |
|
|
152 | (3) |
|
3 Summary and perspective |
|
|
155 | (8) |
|
|
|
158 | (1) |
|
|
|
158 | (5) |
|
7 Targeting cancer-associated fibroblasts in immunotherapy |
|
|
163 | (48) |
|
|
|
|
|
|
|
|
|
163 | (2) |
|
2 CAF and their role in the TME |
|
|
165 | (4) |
|
3 CAF as central regulators of immune cells in the TME |
|
|
169 | (4) |
|
4 CAF-targeting delivery systems |
|
|
173 | (12) |
|
5 CAF targeting in immunotherapy |
|
|
185 | (11) |
|
6 Clinical trials of CAF-targeted immunotherapeutics |
|
|
196 | (3) |
|
7 Challenges and perspectives |
|
|
199 | (12) |
|
|
|
201 | (1) |
|
|
|
201 | (10) |
|
8 Oncolytic viral particle delivery |
|
|
211 | (20) |
|
Faith Hannah Nutter Howard |
|
|
|
|
|
|
1 Background to oncolytic virus delivery |
|
|
211 | (2) |
|
|
|
213 | (5) |
|
3 Pharmacokinetics of nanoparticles in oncology |
|
|
218 | (3) |
|
4 Strategies to enhance delivery |
|
|
221 | (5) |
|
|
|
226 | (5) |
|
|
|
226 | (5) |
|
9 Extracellular vesicles in tumor immunotherapy |
|
|
231 | (26) |
|
|
|
|
|
|
|
|
|
231 | (2) |
|
2 Biogenesis and biological functions of exosomes |
|
|
233 | (5) |
|
3 Exosome immunotherapy applications |
|
|
238 | (6) |
|
|
|
244 | (3) |
|
|
|
247 | (1) |
|
|
|
248 | (9) |
|
|
|
249 | (1) |
|
|
|
249 | (8) |
|
10 Nonviral gene editing in cancer immunotherapy |
|
|
257 | (16) |
|
|
|
|
|
1 Genome editing and intracellular delivery of CRISPR/Cas9 |
|
|
257 | (2) |
|
2 Inorganic nanoparticles |
|
|
259 | (2) |
|
|
|
261 | (3) |
|
4 Lipids and lipid-polymer hybrid materials |
|
|
264 | (3) |
|
5 Challenges and opportunities |
|
|
267 | (6) |
|
|
|
270 | (3) |
|
11 Nucleic acid-based immune checkpoint blockade: Progress and potential |
|
|
273 | (22) |
|
|
|
|
|
|
|
|
|
273 | (1) |
|
2 Nucleic acid constructs and delivery |
|
|
274 | (5) |
|
3 Immunotherapeutic targets for nucleic acid checkpoint treatment |
|
|
279 | (10) |
|
|
|
289 | (6) |
|
|
|
290 | (5) |
|
12 Local and systemic delivery strategies for glioma immunotherapy |
|
|
295 | (38) |
|
|
|
|
|
|
|
|
|
|
|
|
|
295 | (3) |
|
2 Glioma microenvironment and immune responses |
|
|
298 | (7) |
|
3 Immunotherapeutic approaches for glioma |
|
|
305 | (4) |
|
4 Delivery challenges and a need for novel solutions |
|
|
309 | (4) |
|
5 Novel delivery solutions for glioma immunotherapy |
|
|
313 | (13) |
|
6 Challenges in clinical translation and future prospects |
|
|
326 | (1) |
|
|
|
326 | (7) |
|
|
|
328 | (5) |
|
13 Delivery strategies for STING agonists |
|
|
333 | (26) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 The fundamentals of STING biology |
|
|
333 | (7) |
|
2 STING activation in cancer immunotherapy and vaccine adjuvant |
|
|
340 | (19) |
|
|
|
351 | (1) |
|
|
|
352 | (7) |
|
14 Delivery strategies for cancer vaccines and immunoadjuvants |
|
|
359 | (50) |
|
Elizabeth G. Graham-Gurysh |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 | (3) |
|
2 Overview of immune responses important for cancer vaccines |
|
|
362 | (3) |
|
3 Cancer antigens target vaccines |
|
|
365 | (3) |
|
4 Common preclinical cancer models |
|
|
368 | (1) |
|
5 Adjuvants are needed to boost an antigen's immune response |
|
|
369 | (6) |
|
6 Formulation of cancer vaccine adjuvants and antigens |
|
|
375 | (22) |
|
7 Conclusions and future directions |
|
|
397 | (12) |
|
|
|
398 | (1) |
|
|
|
398 | (11) |
|
15 Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer |
|
|
409 | (28) |
|
|
|
|
|
411 | (2) |
|
2 Therapeutic strategies targeting each step of MDSC accumulation and the activities in cancer |
|
|
413 | (1) |
|
3 Targeting expansion and trafficking of MDSCs |
|
|
414 | (4) |
|
4 Potential target of MDSC-mediated immunosuppressive activities |
|
|
418 | (3) |
|
5 Other functions of MDSCs and possible treatment strategies in cancer |
|
|
421 | (1) |
|
6 Differentiate MDSCs into mature, nonsuppressive cells |
|
|
422 | (1) |
|
7 Maximizing other therapies by targeting MDSCs |
|
|
423 | (2) |
|
|
|
425 | (12) |
|
|
|
426 | (11) |
|
16 Delivery of radioimmunotherapy for solid tumors |
|
|
437 | (26) |
|
|
|
|
|
|
|
|
|
|
|
437 | (1) |
|
2 Challenges in delivery of RIT in solid tumors |
|
|
438 | (4) |
|
3 Approaches to enhance the delivery of RIT in solid tumors |
|
|
442 | (8) |
|
4 Conclusions and future perspective |
|
|
450 | (13) |
|
|
|
452 | (1) |
|
|
|
452 | (11) |
|
17 Targeted photodynamic immunotherapy |
|
|
463 | (20) |
|
|
|
|
|
|
|
463 | (3) |
|
2 Photodynamic immunotherapy |
|
|
466 | (10) |
|
3 Limitations and future perspectives |
|
|
476 | (1) |
|
|
|
477 | (6) |
|
|
|
477 | (1) |
|
|
|
477 | (6) |
|
18 Local immunotherapy of cancer and metastasis |
|
|
483 | (46) |
|
|
|
|
|
|
|
484 | (1) |
|
2 Types of cancer immunotherapy |
|
|
485 | (7) |
|
3 Chemotherapy in cancer immunotherapy |
|
|
492 | (2) |
|
4 Delivery of cancer immunotherapy agents |
|
|
494 | (21) |
|
5 Evaluation of local immunotherapy in preclinical studies |
|
|
515 | (5) |
|
|
|
520 | (9) |
|
|
|
520 | (9) |
|
19 Delivery strategies to overcome tumor immunotherapy resistance |
|
|
529 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
529 | (4) |
|
2 Tumor immunotherapy resistance |
|
|
533 | (4) |
|
3 Delivery strategies to overcome tumor immunotherapy resistance |
|
|
537 | (4) |
|
|
|
541 | (1) |
| References |
|
541 | (8) |
| Index |
|
549 | |
